Aertgeerts P, Albring M, Klaschka F, Nasemann T, Patzelt-Wenczler R, Rauhut K, Weigl B
Z Hautkr. 1985 Feb 1;60(3):270-7.
We report on 161 patients suffering from inflammatory dermatoses on hands, forearms, and lower legs who had been initially treated with 0.1% difluocortolone valerate. During the maintenance therapy carried out over a period of 3 to 4 weeks, we tested the efficacy of Kamillosan cream vs. 0.25% hydrocortisone, 0.75% fluocortin butyl ester, and 5% bufexamac in a bilateral comparative study. For the indications tested Kamillosan cream showed more or less equieffective therapeutic results as compared to 0.25% hydrocortisone. It is superior, however, to the non-steroidal anti-inflammatory agent 5% bufexamac as well as to 0.75% fluocortin butyl ester, a further glucocorticoid. With regard to neurodermitis, Kamillosan cream not only shows the same therapeutic effect as 0.25% hydrocortisone but is even of marked superiority towards other reference products.
我们报告了161例手部、前臂和小腿患有炎性皮肤病的患者,他们最初接受了0.1%戊酸二氟可龙治疗。在为期3至4周的维持治疗期间,我们在一项双侧对照研究中测试了Kamillosan乳膏与0.25%氢化可的松、0.75%氟轻松丁酯和5%布地奈德的疗效。对于所测试的适应症,Kamillosan乳膏与0.25%氢化可的松相比显示出或多或少等效的治疗效果。然而,它优于非甾体抗炎药5%布地奈德以及另一种糖皮质激素0.75%氟轻松丁酯。关于神经性皮炎,Kamillosan乳膏不仅显示出与0.25%氢化可的松相同的治疗效果,甚至对其他对照产品具有明显优势。